TITLE

Sustained complete response of hepatocellular carcinoma with portal vein tumor thrombus following discontinuation of sorafenib: A case report

AUTHOR(S)
KAZUE SHIOZAWA; MANABU WATANABE; TAKASHI IKEHARA; YASUSHI MATSUKIYO; MICHIO KOGAME; MASAHIRO KANAYAMA; TEPPEI MATSUI; YOSHINORI KIKUCHI; KOJI ISHII; YOSHINORI IGARASHI; YASUKIYO SUMINO
PUB. DATE
January 2014
SOURCE
Oncology Letters;2014, Vol. 7 Issue 1, p50
SOURCE TYPE
Academic Journal
DOC. TYPE
Case Study
ABSTRACT
Hepatocellular carcinoma (HCC) is the third most common cause of cancer-associated mortality worldwide. No effective treatment has been established for unresectable advanced HCC, and the prognosis is poor. Sorafenib is an oral multi-targeted tyrosine kinase inhibitor for unresectable advanced HCC that significantly improves progression-free and overall survival. However, in the two large phase III clinical trials (the SHARP and Asia-Pacific trials), no cases of complete response (CR) were reported. The present study reports the case of a 68-year-old male with hepatitis C virus-related cirrhosis and multiple recurrent HCCs, with a tumor thrombus of the third portal vein following resection. The patient received 400 mg once daily (half the standard dose) of sorafenib for two years and achieved a CR. At the most recent follow-up examination at one year after the cessation of treatment, the patient was observed to be in remission without clinical or imaging evidence of disease recurrence.
ACCESSION #
95960097

 

Related Articles

  • Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome. Piekarska, Agnieszka; Gil, Lidia; Prejzner, Witold; Wiśniewski, Piotr; Leszczyńska, Aleksandra; Gniot, Michał; Komarnicki, Mieczysław; Hellmann, Andrzej; Wiśniewski, Piotr; Leszczyńska, Aleksandra; Gniot, Michał; Komarnicki, Mieczysław // Annals of Hematology;Nov2015, Vol. 94 Issue 11, p1891 

    Introduction: Allogeneic hematopoietic cell transplantation (HCT) was a standard therapy in chronic phase (CP) chronic myeloid leukemia (CML). As a result of the effective therapy with tyrosine kinase inhibitors (TKI), HCT was shifted to defined clinical situations. We present the...

  • Key Decision Just After 3 Months Following TKI Initiation in CML: Better and not Difficult. HAZNEDAROGLU, Ibrahim C. // International Journal of Hematology & Oncology / UHOD: Uluslarar;2013 Supplement, Vol. 23 Issue 1, p1 

    A letter to the editor is presented regarding the use of tyrosine kinase inhibitor (TKI) in the management of chronic myeloid leukemia (CML) is presented.

  • Indolinone Derivatives Inhibit Constitutively Activated KIT Mutants and Kill Neoplastic Mast Cells. Ma, Yongsheng; Carter, Eric; Wang, Xiaomei; Shu, Chang; McMahon, Gerald; Longley, B. Jack // Journal of Investigative Dermatology;Feb2000, Vol. 114 Issue 2, p392 

    Summary Mastocytosis is a neoplastic disease caused at least in part by somatic mutations of the c-KIT proto-oncogene resulting in constitutive activation of its protein product, KIT, the receptor tyrosine kinase for stem cell factor. KIT stimulates mast cell proliferation and prevents apoptosis...

  • Sorafenib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a male patient who developed occlusive coronary artery disease while undergoing sorafenib therapy for metastatic renal cell carcinoma.

  • Sorafenib/sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a 60-year-old man with clear cell renal cell carcinoma who experienced various toxicities while undergoing sorafenib/sunitinib therapy.

  • Sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p45 

    The article describes the case of a 72-year-old man who developed acute adrenal insufficiency with thyrotoxicosis while undergoing sunitinib therapy for metastatic renal cell carcinoma.

  • Sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p46 

    The article describes the case of a 27-year-old woman who experienced fatigue and heart failure while undergoing sunitinib therapy for gastrointestinal stromal tumour (GIST).

  • Sunitinib.  // Reactions Weekly;10/13/2012, Issue 1423, p46 

    The article describes the case of a 41-year-old woman who developed severe hypothyroidism while undergoing sunitinib therapy for progressive metastatic papillary renal cell cancer.

  • Erlotinib/warfarin interaction.  // Reactions Weekly;6/18/2011, Issue 1356, p16 

    The article describes the case of a 47-year-old man who developed an elevated international normalized ratio (INR) while receiving treatment with erlotinib for lung cancer and warfarin therapy for venous thromboembolism.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics